Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04342026

Role of the Environment and Endocrine Disruptors in Child Cryptorchidism

Status
Recruiting
Phase
Study type
Observational
Enrollment
1,452 (estimated)
Sponsor
University Hospital, Montpellier · Academic / Other
Sex
Male
Age
1 Month – 18 Years
Healthy volunteers
Not accepted

Summary

Cryptorchidism is the most frequent congenital defect of the male newborn. It requires surgery in childhood, increases the risk of fertility disorders and cancer. As a major public health objective, it's the subject of numerous recommendations. Its frequency is increasing in some countries faster than a single genetic cause could not explain it. It may occurs in a geographic cluster. The cause of cryptorchidism involves genetic, hormonal and environmental factors. Animal studies suggest that endocrine disruptors interfere with fetal testicular migration. The aim of the study is to find out if some environmental exposition may be associated with cryptorchidism.

Detailed description

Cryptorchidism is the most frequent congenital defect of the male newborn. It requires surgery in childhood, increases the risk of fertility disorders and cancer. As a major public health objective, it's the subject of numerous recommendations. Its frequency is increasing in some countries faster than a single genetic cause could not explain it. It may occurs in a geographic cluster. The cause of cryptorchidism involves genetic, hormonal and environmental factors. Animal studies suggest that endocrine disruptors interfere with fetal testicular migration. The aim of the study is to find out if some environmental exposition may be associated with cryptorchidism.

Conditions

Interventions

TypeNameDescription
OTHERMeasure of the exposure of parent of male with /without cryptorchidism to endocrine disruptorsMeasure of the exposure of parent of patient with/without cryptorchidism to endocrine disruptors (job exposure, during pregnancy)

Timeline

Start date
2020-04-16
Primary completion
2027-10-15
Completion
2028-04-15
First posted
2020-04-10
Last updated
2025-10-03

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04342026. Inclusion in this directory is not an endorsement.